Novartis Investigative Site

Lancaster, Pennsylvania 17605

0 studies enrolling now · 4 studies all time

What they study most

Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Non-Hodgkin's Lymphoma, Type 2 Diabetes Mellitus

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy — Stopped early
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early